Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2012
04/10/2012US8153625 Nitrogen-containing heterocyclic compounds and medicinal use thereof
04/10/2012US8153581 Process for producing an injectable medicament preparation
04/10/2012US8153398 Polynucleotides encoding signal peptide-containing molecules
04/10/2012US8153384 Marks as modifiers of the p53 pathway and methods of use
04/10/2012US8153172 Composition to enhance the bioavailability of curcumin
04/10/2012US8153141 Immunostimulatory G, U-containing oligoribonucleotides
04/10/2012US8153126 Anti-αvβ6 antibodies
04/10/2012US8153124 Method for treating cancer using monoclonal antibodies
04/10/2012US8153117 Genetically altered chondrocyte expresses a therapeutic agent; implanting a biocompatible substrate into a target region; brain, heart, liver, kidney, intestinal tract, spleen, smooth and skeletal muscles, eye, ganglions, lungs, gonads, pancreas
04/10/2012US8153113 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue
04/10/2012CA2669680C Compounds for inhibiting mitotic progression
04/10/2012CA2634646C Pyrimidine derivatives for the treatment of abnormal cell growth
04/10/2012CA2632567C Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
04/10/2012CA2598893C Eml4-alk fusion gene
04/10/2012CA2537861C Entrapped stem cells and uses thereof
04/10/2012CA2526540C Cyclicamino-phenyl sulfamate derivatives
04/10/2012CA2519980C Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
04/10/2012CA2499822C Novel pyrimidineamide derivatives and the use thereof
04/10/2012CA2491802C Novel compounds, pharmaceutical compositions containing same, and methods of use for same
04/10/2012CA2477857C Stabilized liquid polypeptide-containing pharmaceutical compositions
04/10/2012CA2473754C Treatment of ms with goat serum
04/10/2012CA2445253C Single chain camelid vhh antibodies, method for their production in a mammal, and their uses
04/10/2012CA2399432C Cytotoxic t lymphocytes activated by dendritic cell hybrids
04/10/2012CA2352783C Stimulation of t cells against self antigens using ctla-4 blocking agents
04/10/2012CA2263503C Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
04/10/2012CA2238843C Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof
04/05/2012WO2012045090A2 Therapeutic use of a tlr agonist and combination therapy
04/05/2012WO2012045085A1 Anti-rori antibodies
04/05/2012WO2012045020A1 Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
04/05/2012WO2012045010A1 Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine
04/05/2012WO2012044939A2 Method of preparing a dry powder from a water bacteria extract-concentrate
04/05/2012WO2012044936A1 Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
04/05/2012WO2012044933A2 B and t lymphocyte attenuator marker for use in adoptive t-cell therapy
04/05/2012WO2012044684A2 Interferon-beta for use as monotherapy or in combination with other cancer therapies
04/05/2012WO2012044577A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
04/05/2012WO2012044574A1 Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
04/05/2012WO2012044572A1 Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
04/05/2012WO2012044537A1 Substituted benzimidazole and imidazopyridine compounds useful as cyp17 modulators
04/05/2012WO2012043747A1 Glioma treatment method, glioma examination method, method of delivering a desired material to a glioma, and drug used in said methods
04/05/2012WO2012043710A1 GROWTH-REGULATED VIRAL VECTOR CONTAINING THE Aurora KINASE PROMOTER
04/05/2012WO2012043651A1 Production method for myeloid blood cells
04/05/2012WO2012043634A1 Antibody against human prostaglandin e2 receptor ep4
04/05/2012WO2012043633A1 Inhibitor of expression of dominantly mutated gene
04/05/2012WO2012043549A1 Arctigenin-containing bardanae fructus extract and method for producing same
04/05/2012WO2012043533A1 Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
04/05/2012WO2012043185A1 Composition for inhibiting il-8 expression
04/05/2012WO2012042482A1 Process for the synthesis of funicone analogues
04/05/2012WO2012042480A1 Compositions and methods for treatment of hematological malignancies
04/05/2012WO2012042421A1 Method of treating abnormal cell growth
04/05/2012WO2012042265A1 Novel acridine derivatives
04/05/2012WO2012042024A1 Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers
04/05/2012WO2012041987A1 Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
04/05/2012WO2012041959A1 Treatment of b-cell lymphoma with microrna
04/05/2012WO2012041817A1 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
04/05/2012WO2012041800A1 Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
04/05/2012WO2012041524A1 Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
04/05/2012WO2012041504A1 Amatoxin-conjugates with improved linkers
04/05/2012WO2012041451A1 Thiazolidine linker for the conjugation of drugs to antibodies
04/05/2012WO2012041435A1 Phenylquinazoline derivatives
04/05/2012WO2012041256A1 Anti-cancer extract and compounds
04/05/2012WO2012040824A1 Anti-ceacam6 antibodies and uses thereof
04/05/2012WO2012018854A8 Pactamycin analogs and methods of use
04/05/2012WO2012017239A3 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
04/05/2012WO2012009080A3 Device for radiation-activated localized delivery of treatment agents
04/05/2012WO2011156321A9 Furanyl compounds and the use thereof
04/05/2012WO2011153514A9 The use of inhibitors of bruton's tyrosine kinase (btk)
04/05/2012WO2011153287A3 Materials and methods for diagnosing and predicting the course of prostate cancer
04/05/2012WO2011150279A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
04/05/2012WO2011146594A3 Mtor selective kinase inhibitors
04/05/2012WO2011146410A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
04/05/2012WO2011143482A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
04/05/2012WO2011143317A3 Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
04/05/2012WO2011143201A3 Ratiometric combinatorial drug delivery
04/05/2012WO2011140295A3 Modulators of notch receptor signaling and methods of use thereof
04/05/2012WO2011140135A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
04/05/2012WO2011139867A3 Method of treating brain cancer
04/05/2012WO2011139799A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
04/05/2012WO2011139769A3 Immunogenic compositions and methods for treating neoplasia
04/05/2012WO2011139714A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
04/05/2012WO2011135303A3 Ubiquitination modulators
04/05/2012WO2011133867A3 Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration
04/05/2012WO2011133555A3 Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
04/05/2012WO2011130317A3 Therapeutic agents having reduced toxicity
04/05/2012WO2011127324A3 Antibodies to cd122
04/05/2012WO2011126733A3 Combination therapies: inhibitors of gaba transaminase and nkcc1
04/05/2012WO2011119979A3 Antibodies to muc16 and methods of use thereof
04/05/2012WO2011116226A3 Display of antibody fragments on virus-like particles of rna bacteriophages
04/05/2012WO2011109789A3 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
04/05/2012WO2011020933A8 Liposomes covered with the extracellular domain of the apo2l/trail protein
04/05/2012WO2011011882A8 Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
04/05/2012US20120083588 Neutral amino acid transporter and gene thereof
04/05/2012US20120083532 Novel uses
04/05/2012US20120083530 Thermally Stable Oil-in-Water Emulsions Containing an Oil That Contains Polyunsaturated Fatty Acids
04/05/2012US20120083528 Novel protein kinase modulators and therapeutic uses thereof
04/05/2012US20120083527 Anticancer Agents
04/05/2012US20120083523 Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
04/05/2012US20120083522 Modulation of inflammatory responses by factor xi
04/05/2012US20120083518 Cancer Treatment Targeting BRCA1-IRIS
04/05/2012US20120083514 Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
04/05/2012US20120083513 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use
1 ... 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 ... 2211